Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

• Published in: Scientific reports Vol. 13; no. 1; pp. 20223 - 15
• Main Authors: Saridogan, Turcin, Akcakanat, Argun, Zhao, Ming, Evans, Kurt W., Yuca, Erkan, Scott, Stephen, Kirby, Bryce P., Zheng, Xiaofeng, Ha, Min Jin, Chen, Huiqin, Ng, Patrick K. S., DiPeri, Timothy P., Mills, Gordon B., Rodon Ahnert, Jordi, Damodaran, Senthil, Meric-Bernstam, Funda
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18.11.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208/69; 692/4028/67/1059; 692/4028/67/1347; Animals; Antitumor activity; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Disease Models, Animal; Female; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Fibroblast growth factor receptors; Fibroblasts; Gene expression; Growth factors; Humanities and Social Sciences; Humans; multidisciplinary; Pyrazoles; Pyrimidines - pharmacology; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1 - genetics; Receptor, Fibroblast Growth Factor, Type 2 - metabolism; Receptors, Fibroblast Growth Factor - metabolism; Science; Science (multidisciplinary); Therapeutic targets; Tumors

Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a novel, selective, pan-FGFR inhibitor that inhibits FGFR1-4 at nanomolar concentrations. We...